Cell-based therapies after myocardial injury

  • Hüseyin Ince
  • Christof Stamm
  • Christoph A. Nienaber
Article

Opinion statement

Recent translational research into the emerging field of cardiac cell therapy has paved the way for novel clinical treatment strategies. However, neither the ideal source and type of cell nor the critical quantity and mode of application have yet been defined. In patients who have undergone acute myocardial infarction, several cell-based approaches are currently being evaluated, such as intracoronary delivery of autologous mononuclear bone marrow cells or enriched hematopoietic progenitor cell products; systemic cytokine stimulation with release of bone marrow progenitor cells into the systemic circulation; and both intravenous and intracoronary delivery of allogenic marrow stroma cell-derived cells. There are potentially encouraging data for each of these strategies, based to date on small cohorts with conflicting or equivocal recovery of function. Taken together, it is too early to consider cell therapy for heart disease to be effective. Future setbacks are likely, but both clinicians and basic scientists will eventually introduce more potent cell-based strategies into the clinical arena.

Keywords

Coronary Artery Bypass Graft Acute Myocardial Infarction Ventricular Assist Device Skeletal Myoblast Bone Marrow Progenitor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Okrainec K, Banerjee DK, Eisenberg MJ: Coronary artery disease in the developing world. Am Heart J 2004, 148:7–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Antman EM, Van de Werf F: Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. Circulation 2004, 109:2480–2486.PubMedCrossRefGoogle Scholar
  3. 3.
    Eagle KA, Goodman SG, Avezum A, et al.: Practice variation and missed opportunities for reperfusion in STsegment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002, 359:373–377.PubMedCrossRefGoogle Scholar
  4. 4.
    Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004, 110:e82-e292.PubMedCrossRefGoogle Scholar
  5. 5.
    Klein HM, Ghodsizad A, Borowski A, et al.: Autologous bone marrow-derived stem cell therapy in combination with TMLR. A novel therapeutic option for endstage coronary heart disease: report on 2 cases. Heart Surg Forum 2004, 7:E416-E419.PubMedGoogle Scholar
  6. 6.
    Pagani FD, DerSimonian H, Zawadzka A, et al.: Autologous skeletal myoblasts transplanted to ischemiadamaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 2003, 41:879–888.PubMedCrossRefGoogle Scholar
  7. 7.
    Taylor DA, Atkins BZ, Hungspreugs P, et al.: Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998, 4:929–933.PubMedCrossRefGoogle Scholar
  8. 8.
    Taylor DA: Cell-based myocardial repair: how should we proceed? Int J Cardiol 2004, 95:S8-S12.PubMedCrossRefGoogle Scholar
  9. 9.
    Menasche P, Hagege AA, Scorsin M, et al.: Myoblast transplantation for heart failure. Lancet 2001, 357:279–280.PubMedCrossRefGoogle Scholar
  10. 10.
    Hagege AA, Carrion C, Menasche P, et al.: Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 2003, 361:491–492.PubMedCrossRefGoogle Scholar
  11. 11.
    Leobon B, Garcin I, Menasche P, et al.: Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci U S A 2003, 100:7808–7811.PubMedCrossRefGoogle Scholar
  12. 12.
    Menasche P, Hagege AA, Vilquin JT, et al.: Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003, 41:1078–1083. First study of myoblast transplantation during CABG in humans. First report of possible association of ventricular tachycardia and myoblasts.PubMedCrossRefGoogle Scholar
  13. 13.
    Herreros J, Prosper F, Perez A, et al.: Autologous intramyocardial injection of cultured skeletal muscle derived stem cells in patients with non-acute myocardial infarction. Eur Heart J 2003, 24:2012–2020.PubMedCrossRefGoogle Scholar
  14. 14.
    Siminiak T, Kalawski R, Fiszer D, et al.: Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow-up. Am Heart J 2004, 148:531–537.PubMedCrossRefGoogle Scholar
  15. 15.
    Dib N, Michler RE, Pagani FD, et al.: Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 2005, 112:1748–1755.PubMedCrossRefGoogle Scholar
  16. 16.
    Smits PC, van Geuns RJ, Poldermans D, et al.: Catheterbased intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol 2003, 42:2063–2069.PubMedCrossRefGoogle Scholar
  17. 17.
    Ince H, Petzsch M, Rehders TC, et al.: Transcatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction. J Endovasc Ther 2004, 11:695–704.PubMedCrossRefGoogle Scholar
  18. 18.
    Siminiak T, Fiszer D, Jerzykowska O, et al.: Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of postinfarction myocardial contractility impairment: the POZNAN trial. Eur Heart J 2005, 26:1188–1195.PubMedCrossRefGoogle Scholar
  19. 19.
    Tse HF, Kwong YL, Chan JK, et al.: Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003, 361:47–49.PubMedCrossRefGoogle Scholar
  20. 20.
    Fuchs S, Satler LF, Kornowski R, et al.: Catheter-based autologous bone marrow myocardial injection in nooption patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol 2003, 41:1721–1724.PubMedCrossRefGoogle Scholar
  21. 21.
    Perin EC, Dohmann HF, Borojevic R, et al.: Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003, 107:2294–2302.PubMedCrossRefGoogle Scholar
  22. 22.
    Perin EC, Dohmann HF, Borojevic R, et al.: Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004, 110(suppl 1):II213-II218.PubMedGoogle Scholar
  23. 23.
    Galinanes M, Loubani M, Davies J, et al.: Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant 2004, 13:7–13.PubMedGoogle Scholar
  24. 24.
    Stamm C, Westphal B, Kleine HD, et al.: Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003, 361:45–46. First report of CD133+ cell transplantation in humans.PubMedCrossRefGoogle Scholar
  25. 25.
    Stamm C, Kleine HD, Westphal B, et al.: CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiovasc Surg 2004, 52:152–158.PubMedCrossRefGoogle Scholar
  26. 26.
    Archundia A, Aceves JL, Lopez-Hernandez M, et al.: Direct cardiac injection of G-CSF mobilized bonemarrow stem-cells improves ventricular function in old myocardial infarction. Life Sci 2005, 78:279–283.PubMedCrossRefGoogle Scholar
  27. 27.
    Kuethe F, Richartz BM, Kasper C, et al.: Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans. Int J Cardiol 2005, 100:485–491.PubMedCrossRefGoogle Scholar
  28. 28.
    Erbs S, Linke A, Adams V, et al.: Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res 2005, 97:756–762.PubMedCrossRefGoogle Scholar
  29. 29.
    Strauer BE, Brehm M, Zeus T, et al.: Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 2005, 46:1651–1658.PubMedCrossRefGoogle Scholar
  30. 30.
    Heeschen C, Lehmann R, Honold J, et al.: Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004, 109:1615–1622.PubMedCrossRefGoogle Scholar
  31. 31.
    Kocher AA, Schuster MD, Szabolcs MJ, et al.: Neovascularization of ischemic myocardium by human bonemarrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001, 7:430–436.PubMedCrossRefGoogle Scholar
  32. 32.
    Quirici N, Soligo D, Caneva L, et al.: Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 2001, 115:186–194.PubMedCrossRefGoogle Scholar
  33. 33.
    Strauer BE, Brehm M, Zeus T, et al.: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002, 106:1913–1918.PubMedCrossRefGoogle Scholar
  34. 34.
    Assmus B, Schachinger V, Teupe C, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009–3017.PubMedCrossRefGoogle Scholar
  35. 35.
    Britten MB, Abolmaali ND, Assmus B, et al.: Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003, 108:2212–2218.PubMedCrossRefGoogle Scholar
  36. 36.
    Schächinger V, Assmus B, Britten MB, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004, 44:1690–1699.PubMedCrossRefGoogle Scholar
  37. 37.
    Fernández-Avilés F, San Roman JA, Garcia-Frade J, et al.: Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res 2004, 95:742–748.PubMedCrossRefGoogle Scholar
  38. 38.
    Wollert KC, Meyer GP, Lotz J, et al.: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141–148.PubMedCrossRefGoogle Scholar
  39. 39.
    Bartunek J, Vanderheyden M, Vandekerckhove B, et al.: Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005, 112:I178-I183.PubMedGoogle Scholar
  40. 40.
    Meyer GP, Wollert KC, Lotz J, et al.: Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006, 113:1287–1294. First randomized trial of intracoronary BMC transfer after AMI with a follow-up of 18 months.PubMedCrossRefGoogle Scholar
  41. 41.
    Janssens S, Dubois C, Bogaert J, et al.: Autologous bone marrow-derived stem-cell transfer in patients with STsegment elevation myocardial infarction: doubleblind, randomised controlled trial. Lancet 2006, 367: 113–121. First randomized trial of early intracoronary BMC transfer after AMI.PubMedCrossRefGoogle Scholar
  42. 42.
    Lunde K: Effects on left ventricular function by intracoronary injections of autologous mononuclear bone marrow cells in acute anterior wall myocardial infarction: the ASTAMI randomized controlled trial. Available online at http://scientificsessions.americanheart.org/portal/scientificsession/ ss/lbctnewsrelease14. Accessed November 15, 2005. Important study with a negative result.Google Scholar
  43. 43.
    Schächinger S: Intracoronary infusion of bone marrow-derived progenitor cells in acute myocardial infarction: a randomized, double-blind, placebo-controlled multicenter trial (REPAIR-AMI). Available online at http://scientificsessions.americanheart.org/ portal/scientificsessions/ss/lbctnewsrelease1. Accessed November 13, 2005. First multicenter trial with a very good study design. In contrast to the ASTAMI, this study showed benefical results after intracoronary stem cell transfer in AMI.Google Scholar
  44. 44.
    Kuethe F, Richartz BM, Sayer HG, et al.: Lack of regeneration of myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans with large anterior myocardial infarctions. Int J Cardiol 2004, 97:123–12745.PubMedCrossRefGoogle Scholar
  45. 45.
    Murry CE, Soonpaa MH, Reinecke H, et al.: Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004, 428:664–668.PubMedCrossRefGoogle Scholar
  46. 46.
    Ince H, Petzsch M, Kleine HD, et al.: Prevention of left ventricular remodeling with G-CSF after acute myocardial infarction: final one-year results of the FIRSTLINE-AMI trial (Front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor). Circulation 2005, 112(9 suppl):I73-I80.PubMedGoogle Scholar
  47. 47.
    Shintani S, Murohara T, Ikeda H, et al.: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001, 103:2776–2779.PubMedGoogle Scholar
  48. 48.
    Wojakowski W, Tendera M, Michalowska A, et al.: Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004, 110:3213–3220.PubMedCrossRefGoogle Scholar
  49. 49.
    Leone AM, Rutella S, Bonanno G, et al.: Mobilization of bone marrow derived stem cells after myocardial infarction and left ventricular function. Eur Heart J 2005, 26:1196–1204.PubMedCrossRefGoogle Scholar
  50. 50.
    Valgimigli M, Rigolin GM, Fucili A, et al.: CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004, 110:1209–1212.PubMedCrossRefGoogle Scholar
  51. 51.
    Leone AM, Rutella S, Bonanno G, et al.: Endogenous GCSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol 2006, 111:202–208.PubMedCrossRefGoogle Scholar
  52. 52.
    Ince H, Petzsch M, Kleine HD, et al.: Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction using granulocyte-colony stimulating factor (FIRSTLINE-AMI). Circulation 2005, 112:3097–3106. First randomized trial with a very early application of G-CSF after AMI.PubMedCrossRefGoogle Scholar
  53. 53.
    Zohlnhofer D, Ott I, Mehilli J, et al.: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction, a randomized controlled trial. JAMA 2006, 295:1003–1010. First randomized controlled trial with a very late application of G-CSF after AMI.PubMedCrossRefGoogle Scholar
  54. 54.
    Harada M, Qin Y, Takano H, et al.: G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005, 11:305–311. Important experimental findings for direct cardioprotective effects of G-CSF.PubMedCrossRefGoogle Scholar
  55. 55.
    Valgimigli M, Rigolin GM, Cittanti C, et al.: Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 2005, 26:1838–1845.PubMedCrossRefGoogle Scholar
  56. 56.
    Kuethe F, Figulla HR, Herzau M, et al.: Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 2005, 150:115.PubMedCrossRefGoogle Scholar
  57. 57.
    Suarez de Lezo J, Torres A, Herrera I, et al.: Effects of stem-cell mobilization with recombinant human granulocyte colony stimulating factor in patients with percutaneously revascularized acute anterior myocardial infarction. Rev Esp Cardiol 2005, 58:238–240.CrossRefGoogle Scholar
  58. 58.
    Ripa RS, Jorgensen E, Wang Y, et al.: Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006, 113:1983–1992.PubMedCrossRefGoogle Scholar
  59. 59.
    Kang HJ, Kim HS, Zhang SY, et al.: Effects of intracoronary infusion of peripheral blood stem-cells mobilized with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomized clinical trial. Lancet 2004, 363:751–756.PubMedCrossRefGoogle Scholar
  60. 60.
    Fukuda D, Shimada K, Tanaka A, et al.: Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 2004, 43:18–23.PubMedCrossRefGoogle Scholar
  61. 61.
    Kong D, Melo LG, Gnecchi M, et al.: Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 2004, 110:2039–2046.PubMedCrossRefGoogle Scholar
  62. 62.
    Takamiya M, Okigaki M, Jin D, et al.: Granulocyte colony-stimulating factor-mobilized circulating c-Kit+/ Flk-1+ progenitor cells regenerate endothelium and inhibit neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2006, 26:751–757.PubMedCrossRefGoogle Scholar
  63. 63.
    Jiang Y, Jahagirdar BN, Reinhardt RL, et al.: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41–49.PubMedCrossRefGoogle Scholar
  64. 64.
    Toma C, Pittenger MF, Cahill KS, et al.: Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105:93–98.PubMedCrossRefGoogle Scholar
  65. 65.
    Chen SL, Fang WW, Ye F, et al.: Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004, 94:92–95.PubMedCrossRefGoogle Scholar
  66. 66.
    Katritsis DG, Sotiropoulou PA, Karvouni E, et al.: Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005, 65:321–329.PubMedCrossRefGoogle Scholar
  67. 67.
    Vulliet PR, Greeley M, Halloran SM, et al.: Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet 2004, 363:783–784.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Hüseyin Ince
    • 1
  • Christof Stamm
  • Christoph A. Nienaber
  1. 1.Division of CardiologyUniversity Hospital Rostock, Rostock School of MedicineRostockGermany

Personalised recommendations